tiprankstipranks
Advertisement
Advertisement

VRDN Stock Latest News

Viridian Therapeutics price target raised to $43 from $32 at Wedbush
The FlyViridian Therapeutics price target raised to $43 from $32 at Wedbush
2d ago
VRDN
Viridian Therapeutics price target raised to $38 from $35 at Truist
PremiumThe Fly
Viridian Therapeutics price target raised to $38 from $35 at Truist
2d ago
VRDN
Viridian Therapeutics price target raised to $35 from $34 at RBC Capital
PremiumThe Fly
Viridian Therapeutics price target raised to $35 from $34 at RBC Capital
2d ago
VRDN
Viridian Therapeutics price target raised to $39 from $35 at Goldman Sachs
PremiumThe Fly
Viridian Therapeutics price target raised to $39 from $35 at Goldman Sachs
2d ago
VRDN
Viridian Initiated at Buy as Lumivoa FDA Approval Transitions Company to Commercial Stage; $35 Price Target Reiterated
PremiumRatings
Viridian Initiated at Buy as Lumivoa FDA Approval Transitions Company to Commercial Stage; $35 Price Target Reiterated
3d ago
VRDN
Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform
PremiumThe FlyWells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform
3d ago
VRDN
Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Premium
The Fly
Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
3d ago
VRDN
Analyst Initiates Buy on Viridian, Citing Competitive Lumvoa Launch and Pipeline-Driven Long-Term Growth
Premium
Ratings
Analyst Initiates Buy on Viridian, Citing Competitive Lumvoa Launch and Pipeline-Driven Long-Term Growth
3d ago
VRDN
Viridian Therapeutics announces FDA approval, launch of Lumvoa
PremiumThe Fly
Viridian Therapeutics announces FDA approval, launch of Lumvoa
6d ago
VRDN
Viridian’s VRDN-003 Thyroid Eye Disease Trial Reaches Completion, Resetting the Risk/Reward for Investors
PremiumCompany Announcements
Viridian’s VRDN-003 Thyroid Eye Disease Trial Reaches Completion, Resetting the Risk/Reward for Investors
7d ago
VRDN
Viridian Therapeutics Shareholders Approve Directors and Governance Items
PremiumCompany Announcements
Viridian Therapeutics Shareholders Approve Directors and Governance Items
29d ago
8K
VRDN
Viridian Therapeutics Fully Repays Loan, Ends Agreement
PremiumCompany Announcements
Viridian Therapeutics Fully Repays Loan, Ends Agreement
1M ago
8K
VRDN
Viridian Therapeutics secures WuXi deal for veligrotug manufacturing
PremiumCompany AnnouncementsViridian Therapeutics secures WuXi deal for veligrotug manufacturing
1M ago
8K
VRDN
Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI
Premium
The Fly
Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI
2M ago
VRDN
Viridian Therapeutics price target lowered to $39 from $48 at Stifel
Premium
The Fly
Viridian Therapeutics price target lowered to $39 from $48 at Stifel
2M ago
VRDN
Viridian Therapeutics Raises $359 Million in Offerings
PremiumCompany Announcements
Viridian Therapeutics Raises $359 Million in Offerings
2M ago
8K
VRDN
Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00
PremiumThe Fly
Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00
2M ago
VRDN
Viridian Therapeutics price target raised to $34 from $30 at RBC Capital
PremiumThe Fly
Viridian Therapeutics price target raised to $34 from $30 at RBC Capital
2M ago
VRDN
Viridian Therapeutics: REVEAL-2 Success and Strong Cash Runway Support Buy Rating, $32 Price Target Unchanged
PremiumRatings
Viridian Therapeutics: REVEAL-2 Success and Strong Cash Runway Support Buy Rating, $32 Price Target Unchanged
2M ago
VRDN
Analyst Reiterates Buy as Strong Phase III REVEAL-2 Data Boost Elegrobart’s Regulatory and Commercial Outlook
PremiumRatingsAnalyst Reiterates Buy as Strong Phase III REVEAL-2 Data Boost Elegrobart’s Regulatory and Commercial Outlook
2M ago
VRDN
Viridian Reports Positive Phase 3 Results in Thyroid Eye Disease
Premium
Company Announcements
Viridian Reports Positive Phase 3 Results in Thyroid Eye Disease
2M ago
8K
VRDN
Viridian announces REVEAL-2 phase 3 study met primary endpoint
Premium
The Fly
Viridian announces REVEAL-2 phase 3 study met primary endpoint
2M ago
VRDN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >